category,datetime,headline,id,image,related,source,summary,url
company,1769119140,Clorox to Buy Purell-Maker Gojo for $2.25 Billion,138219700,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,PFE,Yahoo,"Clorox said the all-cash deal, which is being funded with debt, will help it expand further into the health and hygiene categories.",https://finnhub.io/api/news?id=e81d5bc79279124ed54beda3dbbb02bdbe99c79caf9b8597e406e7e704a21c57
company,1769091300,Is BMY's Deep Pipeline the Key to Its Next Growth Phase?,138205782,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,PFE,Yahoo,"BMY spotlights a deep pipeline with multi-billion-dollar potential, key late-stage data readouts ahead, and encouraging uptake of the new schizophrenia drug Cobenfy.",https://finnhub.io/api/news?id=e30052199250baef2f56947ed670fb7e5683f6ed6f976ba74c3672c512b334a9
company,1769087100,Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer,138203897,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,PFE,Yahoo,"PALO ALTO, Calif., January 22, 2026--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy in accordance with the approved product labeling.",https://finnhub.io/api/news?id=32b6ab271b261015fba29f304f4899541789d4a6204cdf144628a9c1e5252262
company,1769082600,"Is Pfizer an Absurdly Cheap Dividend Stock, or Just a Value Trap?",138203177,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,PFE,Yahoo,The healthcare giant has had trouble winning over investors in the past year despite an incredibly low valuation.,https://finnhub.io/api/news?id=07f298a02d55e4a3373b0148c1b694507a0d06628d45254b12dcd36e765afa47
company,1769061810,Vaccine makers feel a chill as US Health Secretary Kennedy's rhetoric becomes reality,138202454,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,PFE,Yahoo,"The unprecedented changes have led to diminished vaccine usage, hurt the investment case for some biotechs, and created a ‌drag that will likely dent revenues and raise costs for companies in the coming years, 15 investors and analysts told Reuters.",https://finnhub.io/api/news?id=0571fc727062c1215eef3cff0485cf64c28e6812a24e8d6860fac5d13466f7fe
company,1769058060,"Johnson & Johnson Crushes Patent, Pricing Probs",138203277,https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png,PFE,Yahoo,The company is vying to become the first among its healthcare peers to make $100 billion in annual revenue.,https://finnhub.io/api/news?id=971947ae35deed5c7aaa36c0437223d901199907bef43ba3a8a0a4c84cedaf7d
